Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United states
Femme et Homme Max 99 ans
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United states
MAJ Il y a 4 ans
A 15 MONTH, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PHASE 3 STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF CP 945,598 IN PREVENTION OF WEIGHT REGAIN IN OBESE SUBJECTS
• To examine the long term efficacy of CP 945,598 in prevention of weight regain in obese or overweight subjects over 12 months after previous weight loss (WL)induced by an 8 week low calorie diet (LC...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United states
MAJ Il y a 4 ans
AN 8 WEEK, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 3 TRIAL OF PREGABALIN (150 600 MG/DAY) IN THE ADJUNCTIVE TREATMENT OF PATIENTS WITH GENERALIZED ANXIETY DISORDER (GAD) WHO HAVE NOT OPTIMALLY RESPONDED TO EXISTING THERAPIES
The primary objective of this study is to evaluate the efficacy of pregabalin as compared to placebo as an adjunctive treatment in patients with GAD who partially responded to a standard GAD treatment...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations